mirtazapine has been researched along with Hyperlipemia in 1 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5% in mean body weight over the course of the study in the mirtazapine group that appeared to reach a plateau at 3 weeks, while no increase was observed in the placebo group." | 5.10 | The effects of mirtazapine on plasma lipid profiles in healthy subjects. ( Ekstrom, RD; Esposito, SM; Ford, AL; Golden, RN; Nicholas, LM, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nicholas, LM | 1 |
| Ford, AL | 1 |
| Esposito, SM | 1 |
| Ekstrom, RD | 1 |
| Golden, RN | 1 |
1 trial available for mirtazapine and Hyperlipemia
| Article | Year |
|---|---|
The effects of mirtazapine on plasma lipid profiles in healthy subjects.
Topics: Adult; Antidepressive Agents, Tricyclic; Body Weight; Cholesterol; Coronary Disease; Dose-Response R | 2003 |